nach oben

Journal of Clinical Immunology

Erschienen in:

01.05.2010

Adoptive-Transfer Effects of Intravenous Immunoglobulin in Autoimmunity

verfasst von: Alan H. Lazarus

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Intravenous immunoglobulin (IVIG) is an effective treatment for a variety of autoimmune and inflammatory conditions. The mechanism of action of IVIG remains poorly understood, but a variety of theories have been suggested. Recent studies in murine models have indicated that some of the ameliorative effects of IVIG in autoimmunity can be repeated by the adoptive transfer of leukocytes that have been primed with IVIG. The active cell component within the leukocyte cell population in immune thrombocytopenia (ITP) was determined to be CD11c⁺ dendritic cells. This review will highlight recent work in murine systems that indicates that the effects of IVIG can be adoptively transferred in some autoimmune diseases and inflammatory states.

Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;317:1228–31. CrossRef

Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh ₀(D)). Blut. 1984;49:29–35. CrossRefPubMed

Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev. 2008;22:103–16. CrossRefPubMed

Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007;26:67–78. CrossRefPubMed

Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98:1095–9. CrossRefPubMed

Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest. 2005;115:155–60. PubMed

Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol. 2006;135:97–100. CrossRefPubMed

Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fcgamma receptors on dendritic cells. Nat Med. 2006;12:688–92. CrossRefPubMed

Marjon KD, Marnell LL, Mold C, Du Clos TW. Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia. J Immunol. 2009;182:1397–403. PubMed

10.

Aoshi T, Zinselmeyer BH, Konjufca V, Lynch JN, Zhang X, Koide Y, et al. Bacterial entry to the splenic white pulp initiates antigen presentation to CD8+ T cells. Immunity. 2008;29:476–86. CrossRefPubMed

11.

Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. 2008;105:19571–8. CrossRefPubMed

12.

Takeda M, Yamada H, Iwabuchi K, Shimada S, Naito M, Sakuragi N, et al. Administration of high-dose intact immunoglobulin has an anti-resorption effect in a mouse model of reproductive failure. Mol Hum Reprod. 2007;13:807–14. CrossRefPubMed

13.

Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758–65. CrossRefPubMed

14.

Shioji K, Kishimoto C, Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res. 2001;89:540–6. CrossRefPubMed

15.

Tha-In T, Metselaar HJ, Tilanus HW, Groothuismink ZM, Kuipers EJ, de Man RA, et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood. 2007;110:3253–62. CrossRefPubMed

16.

Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4 ⁺ CD25 ⁺ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111:715–22. CrossRefPubMed

Titel: Adoptive-Transfer Effects of Intravenous Immunoglobulin in Autoimmunity
verfasst von: Alan H. Lazarus
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe Sonderheft 1/2010
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-010-9410-9

Neu im Fachgebiet Innere Medizin

01.06.2023 | Direkte orale Antikoagulanzien | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Adoptive-Transfer Effects of Intravenous Immunoglobulin in Autoimmunity

Abstract

Neu im Fachgebiet Innere Medizin

VHF nach Schlaganfall: Wie lange mit dem DOAK warten?

Erfolge mit onkolytischen Viren bei Hirn- und Ovarialtumoren

Länger progressionsfrei durch Dreierkombi mit Cabozantinib

Die Kehrseite der Zweit-Generations-Antiandrogene

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2010

Natural IgM Antibodies Against Oxidation-Specific Epitopes

A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs

Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy

Analytical and Functional Aspects of Antibody Sialylation

Cell Death Modulation by Intravenous Immunoglobulin

The Role of IgA and IgA Fc Receptors as Anti-Inflammatory Agents

Neu im Fachgebiet Innere Medizin

VHF nach Schlaganfall: Wie lange mit dem DOAK warten?

Erfolge mit onkolytischen Viren bei Hirn- und Ovarialtumoren

Länger progressionsfrei durch Dreierkombi mit Cabozantinib

Die Kehrseite der Zweit-Generations-Antiandrogene

Update Innere Medizin